- FDA approves Orca Bio’s cell therapy to improve transplant outcomesThe FDA gave the go-ahead to Orca Bio’s T cell therapy that would reduce transplant-related complications for blood cancer patients. The therapy will be branded as Tregzi, an homage to the regulato…Endpoints · 27d ago↗ source
- BridgeBio gets funding for drug launch; United buys into cell therapyElsewhere, Otsuka’s kidney drug hit the goal of a confirmatory trial and Vertex’s CRISPR sickle cell drug secured expanded approval.BioPharma Dive · 27d ago↗ source
- BridgeBio adds $1B as it prepares three more drug launchesBridgeBio Pharma has reloaded with about $1 billion in a preferred equity deal to bolster its reserves ahead of three potential drug launches over the next year. The California biotech, which for y…